UK: A Hard Pill to Swallow

Last Updated: 29 July 2019
Article by Robert Bell

Will the CMA face more rigorous scrutiny of its competition investigations following the Concordia case?

A recent judicial review challenge before the High Court against the Competition & Markets Authority (CMA) for their conduct of a pharmaceutical investigation under the Competition Act 1998 has potentially paved the way for further scrutiny of the CMA's conduct of its investigations at an interim stage. But how likely is it that affected parties will resort to such an approach?

The recent High Court case of Concordia has brought under legal scrutiny for the first time the way the CMA conducts its investigations under the Competition Act 1998 during the currency of the investigation itself.

Normally scrutiny of the CMA's procedures and conduct of their investigation, as well as more substantive questions of evidence and law, are reserved for the consideration of the Competition Appeal Tribunal (CAT) once the CMA has taken its final decision in a case.

Appeals against the CMA's Decisions can be lodged under Section 46 of the Competition Act 1998 by the parties to whom the decision is addressed. For the purposes of Section 46 an appealable decision is a decision that Article 101 or 102 TFEU or the prohibitions under Chapter I or II of Competition Act 1998 have been infringed. Appeals are heard on a full merits basis and can raise procedural irregularities as well as legal and evidential points as grounds for appeal.

In addition to this, aggrieved third parties have the right to challenge a decision under Section 47 of the Competition Act 1998 before the CAT.

A recent example of this was when Skyscanner challenged the CMA in relation to their online hotels booking decision and more particularly the commitments accepted in that case. They alleged that the Commitments the CMA accepted from the parties to the online hotels booking case would incorrectly require third parties to adhere to these Commitments even though they were not party to the proceedings and did not accept them. Skyscanner had responded to the CMA's Second Consultation, expressing the concern that the proposed Commitments in that case could have a negative effect on interbrand competition. The CAT decided that the CMA had acted unreasonably when it effectively ignored Skyscanner's point that it raised on the potential impact of these Commitments in the consultation.

What makes the Concordia case novel is that firstly the CMA's conduct of its investigation is being challenged at an interim stage and secondly the form of challenge in this case is based on judicial review grounds before the High Court and is not a challenge under either Sections 46 or 47 of the Competition Act 1998.

Concordia Case

Competition authorities worldwide have been prominently active in the healthcare sector for some time. Their interest has primarily focused on the activities of pharmaceutical companies and in particular their pricing practices. In the UK there have been a series of excessive pricing cases brought by the CMA against a number of pharmaceutical companies. One such case was the case brought against Concordia.

The facts of the case were as follows. Liothyronine tablets, commonly used to treat hyperthyroidism, were reported to cost the NHS £34 million in 2016 . The same tablets cost only £600,000 in 2006. So why the huge spike? The CMA found this 6,000% rise worthy of investigating and, shortly after in October 2017, dawn raided the pharmaceutical company that produces these tablets, Concordia (now called Advanz Pharma) with authorisation from the UK High Court. In November 2017, the CMA alleged in a Statement of Objections that Advanz Pharma, breached UK and EU competition law by charging excessive and unfair prices in relation to the supply of liothyronine tablets in the UK.

Separately, in December 2016, the CMA fined Pfizer and Flynn Pharma £90 million for the excessive pricing of phenytoin pills which are commonly used to treat epilepsy. Pfizer and Flynn appealed. The decision in this case was important to the CMA as it had several other cases pending including Concordia. In June 2018, the CAT declared that the CMA "misapplied the test for unfair pricing" in a parallel pharmaceutical case and remitted it back to the CMA.

Subsequent to the CAT judgment, the Court of Appeal granted the CMA permission to appeal the CAT's judgment of 7 June 2018 which partially set aside the CMA's decision that fined Pfizer and Flynn for charging excessive prices to the NHS for the sale of anti-epilepsy phenytoin sodium capsules. The Court of Appeal is due to hear the CMA's appeal in November this year.

As this is the lead case on the legal definition of excessive pricing under UK competition law the Court of Appeal's judgment is eagerly awaited.

Parallel to this the CMA became aware of new evidence which suggested that Concordia might be guilty of new infringements. Therefore on 21st January 2019 the CMA issued a Supplementary Statement of Objections to Advanz Pharma in order to expedite the timeframe of its investigation and to avoid further legal enforcement hurdles.

In June 2019 Advanz Pharma launched judicial review proceedings before the High Court calling for a halt in the CMA's probe to await the clarification of the law in the Pfizer-Flynn case.

The Judgment

Judicial review is the main mechanism used by the courts to ensure that bodies exercising public law functions act lawfully and fairly and do not abuse their powers. Their decisions can be subject to legal scrutiny only where all other avenues for appealing the relevant decision have been exhausted.

Therefore to bring a case for judicial review Advanz Pharma had to point to a reviewable decision by the CMA, which it was not possible to otherwise appeal, and finally that the CMA had in some way acted illegally or irrationally in taking that decision or that the decision itself was subject to procedural impropriety.

The detailed judgment has not yet been published at the time of writing so it is not possible to comment in detail on the case. However, Concordia argued in its case that the CMA's supplementary charges as set out in the Supplementary Statement of Objections should be halted pending the outcome of the CMA's Pfizer-Flynn appeal in November. Additionally putting the case on hold while the appeal is pending would avoid unnecessary costs if the regulator succeeds in overturning the tribunal court.

The CMA disagreed about putting the case on hold and said it was normal practice for the CMA to proceed with cases while legal challenges are pending. In addition stopping their investigation into Concordia's pricing would create an impediment to their other enforcement work relating to pharmaceutical pricing.

However the Court dismissed Concordia's case and permitted the CMA's investigation to continue notwithstanding the presence of the outstanding Pfizer-Flynn appeal. The Court added that they were not persuaded by Concordia's arguments and did not believe that there was procedural unfairness or irrational conduct on the part of the CMA.

Conclusion

The interesting aspect of this case is not the individual facts of the case or whether in the circumstances Concordia prevailed or not but the fact that judicial review was used at all to challenge the conduct of the CMA investigation at an interim stage.

Clients often complain at the length of CMA investigations. Hitherto the only traditionally used avenues open to them are to question the conduct of the CMA on procedural grounds by referring issues to the Procedural Officer or the Office of the General Counsel. But these forms of redress are only open to parties in defined circumstances.

So it is likely that there will be further judicial review cases following Concordia which will seek to clarify whether remedies by way of judicial review are accepted as an appropriate avenue
of challenge to the CMA's conduct during the currency of its investigations under
the Competition Act 1998 or will it be regarded as premature. If judicial review applications find favour it would open the CMA to more rigorous scrutiny of its conduct of Competition Act investigations. 

Robert Bell is a Partner at Bryan Cave Leighton Paisner LLP

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions